

DESCRIPTION

Erythropoietin is a glycoprotein which stimulates red blood cell production. It is produced in the kidney and stimulates the division and differentiation of committed erythroid progenitors in the bone marrow. EPOGEN® (Epoetin alfa), a 165 amino acid glycoprotein manufactured by recombinant DNA technology, has the same biological effects as endogenous erythropoietin. It has a molecular weight of 30,400 daltons and is produced by mammalian cells into which the human erythropoietin gene has been introduced. The product contains the identical amino acid sequence of isolated natural erythropoietin.

EPOGEN® is formulated as a sterile, colorless liquid in an isotonic sodium chloride/sodium citrate buffered solution or a sodium chloride/sodium phosphate buffered solution for intravenous (IV) or subcutaneous (SC) administration.

Single-dose, Preservative-free Vial: Each 1 mL of solution contains 2000, 3000, 4000 or 10,000 Units of Epoetin alfa, 2.5 mg Albumin (Human), 5.8 mg sodium citrate, 5.8 mg sodium chloride, and 0.06 mg citric acid in Water for Injection, USP (pH 6.9 ± 0.3). This formulation contains no preservative.

Single-dose, Preservative-free Vial: 1 mL (40,000 Units/mL). Each 1 mL of solution contains 40,000 Units of Epoetin alfa, 2.5 mg Albumin (Human), 1.2 mg sodium phosphate monobasic monohydrate, 1.8 mg sodium phosphate dibasic anhydrate, 0.7 mg sodium citrate, 5.8 mg sodium chloride, and 6.8 mg citric acid in Water for Injection, USP (pH 6.9 ± 0.3). This formulation contains no preservative.

Multidose, Preserved Vial: 2 mL (20,000 Units, 10,000 Units/mL). Each 1 mL of solution contains 10,000 Units of Epoetin alfa, 2.5 mg Albumin (Human), 1.3 mg sodium citrate, 8.2 mg sodium chloride, 0.11 mg citric acid, and 1% benzyl alcohol as preservative in Water for Injection, USP (pH 6.1 ± 0.3).

Multidose, Preserved Vial: 1 mL (20,000 Units/mL). Each 1 mL of solution contains 20,000 Units of Epoetin alfa, 2.5 mg Albumin (Human), 1.3 mg sodium citrate, 8.2 mg sodium chloride, 0.11 mg citric acid, and 1% benzyl alcohol as preservative in Water for Injection, USP (pH 6.1 ± 0.3).

EPOGEN® (Epoetin alfa) 2

CLINICAL PHARMACOLOGY

Chronic Renal Failure Patients

Endogenous production of erythropoietin is normally regulated by the level of tissue oxygenation. Hypoxia and anemia generally increase the production of erythropoietin, which in turn stimulates erythropoiesis.² In normal subjects, plasma erythropoietin levels range from 0.01 to 0.03 Units/mL and increase up to 100- to 1000-fold during hypoxia or anemia.² In contrast, in patients with chronic renal failure (CRF), production of erythropoietin is impaired, and this erythropoietin deficiency is the primary cause of their anemia.^{3,4}

Chronic renal failure is the clinical situation in which there is a progressive and usually irreversible decline in kidney function. Such patients may manifest the sequelae of renal dysfunction, including anemia, but do not necessarily require regular dialysis. Patients with end-stage renal disease (ESRD) are those patients with CRF who require regular dialysis or kidney transplantation for survival.

EPOGEN® has been shown to stimulate erythropoiesis in anemic patients with CRF, including both patients on dialysis and those who do not require regular dialysis.⁴⁻¹³ The first evidence of a response to the three times weekly (TIW) administration of EPOGEN® is an increase in the reticulocyte count within 10 days, followed by increases in the red cell count, hemoglobin, and hematocrit, usually within 2 to 6 weeks.^{4,5} Because of the length of time required for erythro-poiesis — several days for erythroid progenitors to mature and be released into the circulation — a clinically significant increase in hematocrit is usually not observed in less than 2 weeks and may require up to 6 weeks in some patients. Once the hematocrit reaches the suggested target range (30% to 36%), that level can be sustained by EPOGEN® therapy in the absence of iron deficiency and concurrent illnesses.

The rate of hematocrit increase varies between patients and is dependent upon the dose of EPOGEN®, within a therapeutic range of approximately 50 to 300 Units/kg TIW.⁴ A greater biologic response is not observed at doses exceeding 300 Units/kg TIW.⁶ Other factors affecting the rate and extent of response include availability of iron stores, the baseline hematocrit, and the presence of concurrent medical problems.

Zidovudine-treated HIV-infected Patients

Responsiveness to EPOGEN® in HIV-infected patients is dependent upon the endogenous serum erythropoietin level prior to treatment. Patients with endogenous serum erythropoietin levels ≤ 500 mUnits/mL, and who are receiving a dose of zidovudine ≤ 4200 mg/week, may respond to EPOGEN® therapy. Patients with endogenous serum erythropoietin levels > 500 mUnits/mL do not appear to respond to EPOGEN® therapy. In a series of four clinical trials involving 255 patients, 60% to 80% of HIV-infected patients treated with zidovudine had endogenous serum erythropoietin levels ≤ 500 mUnits/mL.

Response to EPOGEN® in zidovudine-treated HIV-infected patients is manifested by reduced transfusion requirements and increased hematocrit.

Cancer Patients on Chemotherapy

Anemia in cancer patients may be related to the disease itself or the effect of concomitantly administered chemotherapeutic agents. EPOGEN® has been shown to increase hematocrit and decrease transfusion requirements after the first month of therapy (months 2 and 3), in anemic cancer patients undergoing chemotherapy.

A series of clinical trials enrolled 131 anemic cancer patients who were receiving cyclic cisplatin- or non cisplatin-containing chemotherapy. Endogenous baseline serum erythropoietin levels varied among patients in these trials with approximately 175% (n = 83/110) having endogenous serum erythropoietin levels ≤ 132 mUnits/mL, and approximately 4% (n = 4/110) of patients having endogenous serum erythropoietin levels > 500 mUnits/mL. In general, patients with lower baseline serum erythropoietin levels responded more vigorously to EPOGEN® than patients with higher baseline erythropoietin levels. Although no specific serum erythropoietin level can be stipulated above which patients would be unlikely to respond to EPOGEN® therapy, treatment of patients with grossly elevated serum erythropoietin levels (eg, > 200 mUnits/mL) is not recommended.

Pharmacokinetics

Intravenously administered EPOGEN® is eliminated at a rate consistent with first order kinetics with a circulating half-life ranging from approximately 4 to 13 hours in adult and pediatric patients with CRF.¹⁴⁻¹⁶ Within the therapeutic dose range, detectable levels of plasma erythropoietin are maintained for at least 24 hours. After SC administration of EPOGEN® to patients with CRF, peak serum levels are achieved within 5 to 24 hours after administration and decline slowly thereafter. There is no apparent difference in half-life between adult patients not on dialysis whose serum creatinine levels were greater than 3, and adult patients maintained on dialysis.

In normal volunteers, the half-life of IV administered EPOGEN® is approximately 20% shorter than the half-life in CRF patients. The pharmacokinetics of EPOGEN® have not been studied in HIV-infected patients.

The pharmacokinetic profile of EPOGEN® in children and adolescents appears to be similar to that of adults. Limited data are available in neonates.¹⁷

It has been demonstrated in normal volunteers that the 10,000 Units/mL citrate-buffered Epoetin alfa formulation and the 40,000 Units/mL phosphate-buffered Epoetin alfa formulation are bioequivalent after SC administration of single 750 Units/kg doses. The C_{max} and t_{1/2} after administration of the phosphate buffered Epoetin alfa formulation were 1.8 ± 0.7 Units/mL and 19.0 ± 5.9 hours (mean ± SD), respectively. The corresponding mean ± SD values for the citrate-buffered Epoetin alfa formulation were 2 ± 0.9 Units/mL and 16.3 ± 3.0 hours. There was no notable accumulation in serum after two weekly 750 Units/kg SC doses of Epoetin alfa.

INDICATIONS AND USAGE

Treatment of Anemia of Chronic Renal Failure Patients

EPOGEN® is indicated for the treatment of anemia associated with CRF, including patients on dialysis (ESRD) and patients not on dialysis. EPOGEN® is indicated to elevate or maintain the red blood cell level (as manifested by the hematocrit or hemoglobin determinations) and to decrease the need for transfusions in these patients.

Non-dialysis patients with symptomatic anemia considered for therapy should have a hematocrit less than 30%.

EPOGEN® is not intended for patients who require immediate correction of severe anemia. EPOGEN® may obviate the need for maintenance transfusions but is not a substitute for emergency transfusion.

Prior to initiation of therapy, the patient's iron stores should be evaluated. Transferrin saturation should be at least 20% and ferritin at least 100 ng/mL. Blood pressure should be adequately controlled prior to initiation of EPOGEN® therapy, and must be closely monitored and controlled during therapy.

EPOGEN® should be administered under the guidance of a qualified physician (see DOSAGE AND ADMINISTRATION).

EPOGEN® (Epoetin alfa) 3

Treatment of Anemia in Zidovudine-treated HIV-infected Patients

EPOGEN® is indicated for the treatment of anemia related to therapy with zidovudine in HIV-infected patients. EPOGEN® is indicated to elevate or maintain the red blood cell level (as manifested by the hematocrit or hemoglobin determinations) and to decrease the need for transfusions in these patients. EPOGEN® is not indicated for the treatment of anemia in HIV-infected patients due to other factors such as iron or folate deficiencies, hemolysis, or gastrointestinal bleeding, which should be managed appropriately.

EPOGEN®, at a dose of 100 Units/kg TIW, is effective in decreasing the transfusion requirement and increasing the red blood cell level of anemic, HIV-infected patients treated with zidovudine, when the endogenous serum erythropoietin level is ≤ 500 mUnits/mL and when patients are receiving a dose of zidovudine ≤ 4200 mg/week.

Treatment of Anemia in Cancer Patients on Chemotherapy

EPOGEN® is indicated for the treatment of anemia in patients with non-myeloid malignancies where anemia is due to the effect of concomitantly administered chemotherapy. EPOGEN® is indicated to decrease the need for transfusions in patients who will be receiving concomitant chemotherapy for a minimum of 2 months. EPOGEN® is not indicated for the treatment of anemia in cancer patients due to other factors such as iron or folate deficiencies, hemolysis, or gastrointestinal bleeding, which should be managed appropriately.

Reduction of Allogeneic Blood Transfusion in Surgery Patients

EPOGEN® is indicated for the treatment of anemic patients (hemoglobin > 10 to ≤ 13 g/dL) scheduled to undergo elective, noncardiac, nonvascular surgery to reduce the need for allogeneic blood transfusions.¹⁸⁻²⁰ EPOGEN® is indicated for patients at high risk for perioperative transfusions with significant, anticipated blood loss. EPOGEN® is not indicated for anemic patients who are willing to donate autologous blood. The safety of the perioperative use of EPOGEN® has been studied only in patients who are receiving anticoagulant prophylaxis.

CLINICAL EXPERIENCE: RESPONSE TO EPOGEN®

Chronic Renal Failure Patients

Response to EPOGEN® was consistent across all studies. In the presence of adequate iron stores (see IRON EVALUATION), the time to reach the target hematocrit is a function of the baseline hematocrit and the rate of hematocrit rise.

The rate of increase in hematocrit is dependent upon the dose of EPOGEN® administered and individual patient variation. In clinical trials at starting doses of 50 to 150 Units/kg TIW, adult patients responded with an average rate of rise of hematocrit rise of:

Starting Dose (TIW IV)	Hematocrit Increase	
	Points/Day	Points/2 Weeks
50 Units/kg	0.11	1.5
100 Units/kg	0.18	2.5
150 Units/kg	0.25	3.5

Over this dose range, approximately 95% of all patients responded with a clinically significant increase in hematocrit, and by the end of approximately 2 months of therapy virtually all patients were transfusion-independent. Changes in the quality of life of adult patients treated with EPOGEN® were assessed as part of a phase 3 clinical trial.^{5,8} Once the target hematocrit (32% to 38%) was achieved, statistically significant improvements were demonstrated for most quality of life parameters measured, including energy and activity level, functional ability, sleep and eating behavior, health status, satisfaction with health, sex life, well-being, psychological effect, life satisfaction, and happiness. Patients also reported improvement in their disease symptoms. They showed a statistically significant increase in exercise capacity (VO₂ max), energy, and strength with a significant reduction in aching, dizziness, anxiety, shortness of breath, muscle weakness, and leg cramps.^{8,21}

Adult Patients on Dialysis Thirteen clinical studies were conducted, involving IV administration to a total of 1010 anemic patients on dialysis for 986 patient-years of EPOGEN® therapy. In the three largest of these clinical trials, the median maintenance dose necessary to maintain the hematocrit between 30% to 36% was approximately 75 Units/kg TIW. In the US multicenter phase 3 study, approximately 65% of the patients required doses of 100 Units/kg TIW, or less, to maintain their hematocrit at approximately 35%. Almost 10% of patients required a dose of 25 Units/kg, or less, and approximately 10% required a dose of more than 200 Units/kg TIW to maintain their hematocrit at this level.

A multicenter unit dose study was also conducted in 119 patients receiving peritoneal dialysis who self-administered EPOGEN® subcutaneously for approximately 109 patient-years of experience. Patients responded to EPOGEN® administered SC in a manner similar to patients receiving IV administration.²²

Pediatric Patients on Dialysis One hundred twenty-eight children from 2 months to 19 years of age with CRF requiring dialysis were enrolled in 4 clinical studies of EPOGEN®. The largest study was a placebo-controlled, randomized trial in 113 children with anemia (hematocrit ≤ 27%) undergoing peritoneal dialysis or hemodialysis. The initial dose of EPOGEN® was 50 Units/kg IV or SC TIW. The dose of study drug was titrated to achieve either a hematocrit of 30% to 36% or an absolute increase in hematocrit of 6 percentage points over baseline.

At the end of the initial 12 weeks, a statistically significant rise in mean hematocrit (9.4% vs 0.9%) was observed only in the EPOGEN® arm. The proportion of children achieving a hematocrit of 30%, or an increase in hematocrit of 6 percentage points over baseline, at any time during the first 12 weeks was higher in the EPOGEN® arm (96% vs 58%). Within 12 weeks of initiating EPOGEN® therapy, 92.3% of the pediatric patients were transfusion-independent as compared to 65.4% who received placebo. Among patients who received 36 weeks of EPOGEN®, hemodialysis patients required a higher median maintenance dose (167 Units/kg/week [n = 28] vs 76 Units/kg/week [n = 36]) and took longer to achieve a hematocrit of 30% to 36% (median time to response 69 days vs 32 days) than patients undergoing peritoneal dialysis.

Patients With CRF Not Requiring Dialysis

Four clinical trials were conducted in patients with CRF not on dialysis involving 181 patients treated with EPOGEN® for approximately 67 patient-years of experience. These patients responded to EPOGEN® therapy in a manner similar to that observed in patients on dialysis. Patients with CRF not on dialysis demonstrated a dose-dependent and sustained increase in hematocrit when EPOGEN® was administered by either an IV or SC route, with similar rates of rise of hematocrit when EPOGEN® was administered by either route. Moreover, EPOGEN® doses of 75 to 150 Units/kg per week have been shown to maintain hematocrits of 36% to 38% for up to 6 months. Correcting the anemia of progressive renal failure will allow patients to remain active even though their renal function continues to decrease.^{23,24}

EPOGEN® (Epoetin alfa) 4

Zidovudine-treated HIV-infected Patients

EPOGEN® has been studied in four placebo-controlled trials enrolling 297 anemic (hematocrit < 30%) HIV-infected (AIDS) patients receiving concomitant therapy with zidovudine (all patients were treated with Epoetin alfa manufactured by Amgen Inc. [Amgen]). In the subgroup of patients (89/125 EPOGEN® and 88/130 placebo) with prestudy endogenous serum erythropoietin levels ≤ 500 mUnits/mL, EPOGEN® reduced the mean cumulative number of units of blood transfused per patient by approximately 40% as compared to the placebo group.²⁵ Among those patients who required transfusions at baseline, 43% of patients treated with EPOGEN® versus 18% of placebo-treated patients were transfusion-independent during the second and third months of therapy. EPOGEN® therapy also resulted in significant increases in hematocrit in comparison to placebo. When examining the results according to the weekly dose of zidovudine received during month 3 of therapy, there was a statistically significant (p < 0.003) reduction in transfusion requirements in patients treated with EPOGEN® (n = 51) compared to placebo treated patients (n = 54) whose mean weekly zidovudine dose was ≤ 4200 mg/week.²⁵

Approximately 17% of the patients with endogenous serum erythropoietin levels ≤ 500 mUnits/mL receiving EPOGEN® in doses from 100 to 200 Units/kg TIW achieved a hematocrit of 38% without administration of transfusions or significant reduction in zidovudine dose. In the subgroup of patients whose prestudy endogenous serum erythropoietin levels were > 500 mUnits/mL, EPOGEN® therapy did not reduce transfusion requirements or increase hematocrit, compared to the corresponding responses in placebo-treated patients.

In a 6 month open-label EPOGEN® study, patients responded with decreased transfusion requirements and sustained increases in hematocrit and hemoglobin with doses of EPOGEN® up to 300 Units/kg TIW.²⁵⁻²⁷

Responsiveness to EPOGEN® therapy may be blunted by intercurrent infectious/inflammatory episodes and by an increase in zidovudine dosage. Consequently, the dose of EPOGEN® must be titrated based on these factors to maintain the desired erythropoietic response.

Cancer Patients on Chemotherapy

EPOGEN® has been studied in a series of placebo-controlled, double-blind trials in a total of 131 anemic cancer patients. Within this group, 72 patients were treated with concomitant non cisplatin-containing chemotherapy regimens and 59 patients were treated with concomitant cisplatin-containing chemotherapy regimens. Patients were randomized to EPOGEN® 150 Units/kg or placebo subcutaneously TIW for 12 weeks.

EPOGEN® therapy was associated with a significantly (p < 0.008) greater hematocrit response than in the corresponding placebo-treated patients (see table).²⁵

Hematocrit (%): Mean Change From Baseline to Final Value*		
Study	EPOGEN®	Placebo
Chemotherapy	7.6	1.3
Cisplatin	6.9	0.6
*Significantly higher in EPOGEN® patients than in placebo patients (p < 0.008)		

In the two types of chemotherapy studies (utilizing an EPOGEN® dose of 150 Units/kg TIW), the mean number of units of blood transfused per patient after the first month of therapy was significantly (p < 0.02) lower in patients treated with EPOGEN® (0.71 units in months 2, 3) than in corresponding placebo-treated patients (1.84 units in months 2, 3). Moreover, the proportion of patients transfused during months 2 and 3 of therapy combined was significantly (p < 0.03) lower in the patients treated with EPOGEN® than in the corresponding placebo-treated patients (22% vs 43%).²⁵

Comparable intensity of chemotherapy in the EPOGEN® and placebo groups in the chemotherapy trials was suggested by a similar area under the neutrophil time curve in patients treated with EPOGEN® and placebo-treated patients as well as by a similar proportion of patients in groups treated with EPOGEN® and placebo-treated groups whose absolute neutrophil counts fell below 1000 cells/μL. Available evidence suggests that patients with lymphoid and solid cancers respond equivalently to EPOGEN® therapy, and that patients with or without tumor infiltration of the bone marrow respond equivalently to EPOGEN® therapy.

Surgery Patients

EPOGEN® has been studied in a placebo-controlled, double-blind trial enrolling 316 patients scheduled for major, elective orthopedic hip or knee surgery who were expected to require ≥ 2 units of blood and who were not able or willing to participate in an autologous blood donation program. Based on previous studies which demonstrated that pretreatment hemoglobin is a predictor of risk of receiving transfusion,^{20,28} patients were stratified into one of three groups based on their pretreatment hemoglobin (≤ 10 [n = 2], > 10 to ≤ 13 [n = 96], and > 13 to ≤ 15 g/dL [n = 218]) and then randomly assigned to receive 300 Units/kg EPOGEN®, 100 Units/kg EPOGEN® or placebo by SC injection for 10 days before surgery, on the day of surgery, and for 4 days after surgery.¹⁸ All patients received oral iron and a low-dose post-operative warfarin regimen.¹⁸

Treatment with EPOGEN® 300 Units/kg significantly (p = 0.024) reduced the risk of allogeneic transfusion in patients with a pretreatment hemoglobin of > 10 to ≤ 13 g/dL; 5/31 (16%) of EPOGEN® 300 Units/kg, 6/26 (23%) of EPOGEN® 100 Units/kg, and 13/29 (45%) of placebo-treated patients were transfused.¹⁸ There was no significant difference in the number of patients transfused before surgery (EPOGEN® (9% 300 Units/kg, 6% 100 Units/kg) and placebo (13%) in the > 13 to ≤ 15 g/dL hemoglobin stratum. There were too few patients in the ≤ 10 g/dL group to determine if EPOGEN® is useful in this hemoglobin strata. In the > 10 to ≤ 13 g/dL pretreatment stratum, the mean number of units transfused per EPOGEN®-treated patient (0.45 units blood for 300 Units/kg, 0.42 units blood for 100 Units/kg) was less than the mean transfused per placebo-treated patient (1.14 units) (overall p = 0.028). In addition, mean hemoglobin, hematocrit, and reticulocyte counts increased significantly during the presurgery period in patients treated with EPOGEN®.¹⁸

EPOGEN® was also studied in an open-label, parallel-group trial enrolling 145 subjects with a pretreatment hemoglobin level of ≥ 10 to ≤ 13 g/dL who were scheduled for major orthopedic hip or knee surgery and who were not participating in an autologous program.¹⁹ Subjects were randomly assigned to receive one of two SC dosing regimens of EPOGEN® (600 Units/kg once weekly for 3 weeks prior to surgery and on the day of surgery, or 300 Units/kg once daily for 10 days prior to surgery, on the day of surgery, and for 4 days after surgery). All subjects received oral iron and appropriate pharmacologic anticoagulation therapy.

From pretreatment to presurgery, the mean increase in hemoglobin in the 600 Units/kg weekly group (1.44 g/dL) was greater than observed in the 300 Units/kg daily group.¹⁹ The mean increase in absolute reticulocyte count was smaller in the

EPOGEN® (Epoetin alfa) 5

weekly group (0.11 x 10⁶/mm³) compared to the daily group (0.17 x 10⁶/mm³). Mean hemoglobin levels were similar for the two treatment groups throughout the postsurgical period.

The erythropoietic response observed in both treatment groups resulted in similar transfusion rates (11/69 [16%] in the 600 Units/kg weekly group and 14/71 [20%] in the 300 Units/kg daily group).¹⁹ The mean number of units transfused per subject was approximately 0.3 units in both treatment groups.

CONTRAINDICATIONS

EPOGEN® is contraindicated in patients with:

- Uncontrolled hypertension.
- Known hypersensitivity to mammalian cell-derived products.
- Known hypersensitivity to Albumin (Human).

WARNINGS

Pediatric Use

The multidose preserved formulation contains benzyl alcohol. Benzyl alcohol has been reported to be associated with an increased incidence of neurological and other complications in premature infants which are sometimes fatal.

Thrombotic Events and Increased Mortality

A randomized, prospective trial of 1265 hemodialysis patients with clinically evident cardiac disease (ischemic heart disease or congestive heart failure) was conducted in which patients were assigned to EPOGEN® treatment targeted to a maintenance hematocrit of either 42 ± 3% or 30 ± 3%.⁴² Increased mortality was observed in 634 patients randomized to a target hematocrit of 42% (221 deaths [35% mortality]) compared to 631 patients targeted to remain at a hematocrit of 30% (185 deaths [29% mortality]). The reason for the increased mortality observed in these studies is unknown, however, the incidence of non-fatal myocardial infarctions (3.1% vs 2.3%), vascular access thromboses (39% vs 29%), and all other thrombotic events (22% vs 18%) were also higher in the group randomized to achieve a hematocrit of 42%.

Increased mortality was also observed in a randomized placebo-controlled study of EPOGEN® in adult patients who did not have CRF who were undergoing coronary artery bypass surgery (7 deaths in 126 patients randomized to EPOGEN® versus no deaths among 56 patients receiving placebo). Four of these deaths occurred during the period of study drug administration and all four deaths were associated with thrombotic events. While the extent of the population affected is unknown, in patients at risk for thrombosis, the anticipated benefits of EPOGEN® treatment should be weighed against the potential for increased risks associated with therapy.

Pure Red Cell Aplasia

Pure red cell aplasia (PRCA), in association with neutralizing antibodies to native erythropoietin, has been observed in patients treated with recombinant erythropoietins. PRCA has been reported in a limited number of patients exposed to EPOGEN®. This has been reported predominantly in patients with CRF. Any patient with loss of response to EPOGEN® should be evaluated for the etiology of loss of effect (see PRECAUTIONS: LACK OR LOSS OF RESPONSE). EPOGEN® should be discontinued in any patient with evidence of PRCA and the patient evaluated for the presence of binding and neutralizing antibodies to EPOGEN®, native erythropoietin, and any other recombinant erythropoietin administered to the patient. Amgen/Ortho Biotech Products, L.P. should be contacted to assist in this evaluation. In patients with PRCA secondary to neutralizing antibodies to erythropoietin, EPOGEN® should not be administered and such patients should not be switched to another product as anti-erythropoietin antibodies cross-react with other erythropoietins (see ADVERSE REACTIONS).

Chronic Renal Failure Patients

Hypertension: Patients with uncontrolled hypertension should not be treated with EPOGEN®; blood pressure should be controlled adequately before initiation of therapy. Up to 80% of patients with CRF have a history of hypertension.²⁹ Although there does not appear to be any direct pressor effects of EPOGEN®, blood pressure may rise during EPOGEN® therapy. During the early phase of treatment when the hematocrit is increasing, approximately 25% of patients on dialysis may require initiation of, or increases in, antihypertensive therapy. Hypertensive encephalopathy and seizures have been observed in patients with CRF treated with EPOGEN®.

Special care should be taken to closely monitor and aggressively control blood pressure in patients treated with EPOGEN®. Patients should be advised as to the importance of compliance with antihypertensive therapy and dietary restrictions. If blood pressure is difficult to control by initiation of appropriate measures, the hematocrit may be reduced by decreasing or withholding the dose of EPOGEN®. A clinically significant decrease in hematocrit may not be observed for several weeks.

It is recommended that the dose of EPOGEN® be decreased if the hematocrit increase exceeds 4 points in any 2-week period, because of the possible association of excessive rate of rise of hematocrit with an exacerbation of hypertension. In CRF patients on hemodialysis with clinically evident ischemic heart disease or congestive heart failure, the hematocrit should be managed carefully, not to exceed 36% (see THROMBOTIC EVENTS).

Seizures: Seizures have occurred in patients with CRF participating in EPOGEN® clinical trials.

In adult patients on dialysis, there was a higher incidence of seizures during the first 90 days of therapy (occurring in approximately 2.5% of patients) as compared with later timepoints.

Given the potential for an increased risk of seizures during the first 90 days of therapy, blood pressure and the presence of premonitory neurologic symptoms should be monitored closely. Patients should be cautioned to avoid potentially hazardous activities such as driving or operating heavy machinery during this period.

While the relationship between seizures and the rate of rise of hematocrit is uncertain, *it is recommended that the dose of EPOGEN® be decreased if the hematocrit increase exceeds 4 points in any 2-week period.*

Thrombotic Events: During hemodialysis, patients treated with EPOGEN® may require increased anticoagulation with heparin to prevent clotting of the artificial kidney (see ADVERSE REACTIONS for more information about thrombotic events).

Other thrombotic events (eg, myocardial infarction, cerebrovascular accident, transient ischemic attack) have occurred in clinical trials at an annualized rate of less than 0.04 events per patient year of EPOGEN® therapy. These trials were conducted in adult patients with CRF (whether on dialysis or not) in whom the target hematocrit was 32% to 40%. However, the risk of thrombotic events, including vascular access thrombosis, was significantly increased in adult patients with ischemic heart disease or congestive heart failure receiving EPOGEN® therapy with the goal of reaching a normal hematocrit (42%) as compared to a target hematocrit of 30%. Patients with pre-existing cardiovascular disease should be monitored closely.

EPOGEN® (Epoetin alfa) 6

Zidovudine-treated HIV-infected Patients

In contrast to CRF patients, EPOGEN® therapy has not been linked to exacerbation of hypertension, seizures, and thrombotic events in HIV-infected patients.

PRECAUTIONS

The parenteral administration of any biologic product should be attended by appropriate precautions in case allergic or other untoward reactions occur (see CONTRAINDICATIONS). In clinical trials, while transient rashes were occasionally observed concurrently with EPOGEN® therapy, no serious allergic or anaphylactic reactions were reported (see ADVERSE REACTIONS for more information regarding allergic reactions).

The safety and efficacy of EPOGEN® therapy have not been established in patients with a known history of a seizure disorder or underlying hematologic disease (eg, sickle cell anemia, myelodysplastic syndromes, or hypercoagulable disorders).

In some female patients, menses have resumed following EPOGEN® therapy; the possibility of pregnancy should be discussed and the need for contraception evaluated.

Hematology

Exacerbation of porphyria has been observed rarely in patients with CRF treated with EPOGEN®. However, EPOGEN® has not caused increased urinary excretion of porphyrin metabolites in normal volunteers, even in the presence of a rapid erythropoietic response. Nevertheless, EPOGEN® should be used with caution in patients with known porphyria.

In preclinical studies in dogs and rats, but not in monkeys, EPOGEN® therapy was associated with subclinical bone marrow fibrosis. Bone marrow fibrosis is a known complication of CRF in humans and may be related to secondary hyperparathyroidism or unknown factors. The incidence of bone marrow fibrosis was not increased in a study of adult patients on dialysis who were treated with EPOGEN® for 12 to 19 months, compared to the incidence of bone marrow fibrosis in a matched group of patients who had not been treated with EPOGEN®.

Hematocrit in CRF patients should be measured twice a week; zidovudine-treated HIV-infected and cancer patients should have hematocrit measured once a week until hematocrit has been stabilized, and measured periodically thereafter.

Lack or Loss of Response

If the patient fails to respond or to maintain a response to doses within the recommended dosing range, the following etiologies should be considered and evaluated:

- Iron deficiency: Virtually all patients will eventually require supplemental iron therapy (see IRON EVALUATION).
- Underlying infectious, inflammatory, or malignant processes.
- Occult blood loss.
- Underlying hematologic diseases (ie, thalassemia, refractory anemia, or other myelodysplastic disorders).
- Vitamin deficiencies: Folic acid or vitamin B12.
- Hemolysis.
- Aluminum intoxication.
- Osteitis fibrosa cystica.

In the absence of another etiology, the patient should be evaluated for evidence of PRCA and sera should be tested for the presence of antibodies to recombinant erythropoietins.

Iron Evaluation

EPOGEN® (Epoetin alfa)	8
------------------------	---

Zidovudine-treated HIV-infected Patients

Hypertension

Exacerbation of hypertension has not been observed in zidovudine-treated HIV-infected patients treated with EPOGEN®. However, EPOGEN® should be withheld in these patients if pre-existing hypertension is uncontrolled, and should not be started until blood pressure is controlled. In double-blind studies, a single seizure has been experienced by a patient treated with EPOGEN®.²⁵

Cancer Patients on Chemotherapy

Hypertension

Hypertension, associated with a significant increase in hematocrit, has been noted rarely in patients treated with EPOGEN®. Nevertheless, blood pressure in patients treated with EPOGEN® should be monitored carefully, particularly in patients with an underlying history of hypertension or cardiovascular disease.

Seizures

In double-blind, placebo-controlled trials, 3.2% (n = 2/63) of patients treated with EPOGEN® and 2.9% (n = 2/68) of placebo-treated patients had seizures. Seizures in 1.6% (n = 1/63) of patients treated with EPOGEN® occurred in the context of a significant increase in blood pressure and hematocrit from baseline values. However, both patients treated with EPOGEN® also had underlying CNS pathology which may have been related to seizure activity.

Thrombotic Events

In double-blind, placebo-controlled trials, 3.2% (n = 2/63) of patients treated with EPOGEN® and 11.8% (n = 8/68) of placebo-treated patients had thrombotic events (eg, pulmonary embolism, cerebrovascular accident).

Growth Factor Potential

EPOGEN® is a growth factor that primarily stimulates red cell production.

However, the possibility that EPOGEN® can act as a growth factor for any tumor type, particularly myeloid malignancies, cannot be excluded.

Surgery Patients

Thrombotic/Vascular Events

In perioperative clinical trials with orthopedic patients, the overall incidence of thrombotic/vascular events was similar in Epoetin alfa and placebo-treated patients who had a pretreatment hemoglobin of > 10 to ≤ 13 g/dL. In patients with a hemoglobin of > 13 g/dL treated with 300 Units/kg of Epoetin alfa, the possibility that EPOGEN® treatment may be associated with an increased risk of postoperative thrombotic/vascular events cannot be excluded.^{18,20, 28}

In one study in which Epoetin alfa was administered in the perioperative period to patients undergoing coronary artery bypass graft surgery, there were 7 deaths in the group treated with Epoetin alfa (n = 126) and no deaths in the placebo-treated group (n = 56). Among the 7 deaths in the patients treated with Epoetin alfa, 4 were at the time of therapy (between study day 2 and 8). The 4 deaths at the time of therapy (3%) were associated with thrombotic/vascular events. A causative role of Epoetin alfa cannot be excluded (see WARNINGS).

Hypertension

Blood pressure may rise in the perioperative period in patients being treated with EPOGEN®. Therefore, blood pressure should be monitored carefully.

ADVERSE REACTIONS

Immunogenicity

As with all therapeutic proteins, there is the potential for immunogenicity. Cases of antibody-induced PRCA in patients treated with recombinant human erythropoietins have been described in publications.^{43,44}

Very rare occurrences of PRCA and the presence of antibodies with neutralizing activity have been reported since market introduction of EPOGEN® in the United States (see WARNINGS: PURE RED CELL APLASIA). Cases have been observed in patients treated by both SC and IV routes of administration. Among reported cases where the route of administration is known, PRCA has been observed more with SC administration than IV administration.

The incidence of antibody formation is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody positivity in an assay may be influenced by several factors including sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies to EPOGEN® with the incidence of antibodies to other products may be misleading.

Chronic Renal Failure Patients

EPOGEN® is generally well-tolerated. The adverse events reported are frequent sequelae of CRF and are not necessarily attributable to EPOGEN® therapy. In double-blind, placebo-controlled studies involving over 300 patients with CRF, the events reported in greater than 5% of patients treated with EPOGEN® during the blinded phase were:

Event	Percent of Patients Reporting Event	
	Patients Treated With EPOGEN® (n = 200)	Placebo-treated Patients (n = 135)
Hypertension	24%	19%
Headache	16%	12%
Arthralgias	11%	6%
Nausea	11%	9%
Edema	9%	10%
Fatigue	9%	14%
Diarrhea	9%	6%
Vomiting	8%	5%
Chest Pain	7%	9%
Skin Reaction (Administration Site)	7%	12%
Asthenia	7%	12%
Dizziness	7%	13%
Clotted Access	7%	2%

Significant adverse events of concern in patients with CRF treated in double-blind, placebo-controlled trials occurred in the following percent of patients during the blinded phase of the studies:

Seizure	1.1%	1.1%
CVA/TIA	0.4%	0.6%
MI	0.4%	1.1%
Death	0%	1.7%

In the US EPOGEN® studies in adult patients on dialysis (over 567 patients), the incidence (number of events per patient-year) of the most frequently reported adverse events were: hypertension (0.75), headache (0.40), tachycardia (0.31), nausea/vomiting (0.26), clotted vascular access (0.25), shortness of breath (0.14), hyperkalemia (0.11), and diarrhea (0.11). Other reported events occurred at a rate of less than 0.10 events per patient per year.

EPOGEN® (Epoetin alfa)	9
------------------------	---

Events reported to have occurred within several hours of administration of EPOGEN® were rare, mild, and transient, and included injection site stinging in dialysis patients and flu-like symptoms such as arthralgias and myalgias.

In all studies analyzed to date, EPOGEN® administration was generally well-tolerated, irrespective of the route of administration.

Pediatric CRF Patients: In pediatric patients with CRF on dialysis, the pattern of most adverse events was similar to that found in adults. Additional adverse events reported during the double-blind phase in >10% of pediatric patients in either treatment group were: abdominal pain, dialysis access complications including access infections and peritonitis in those receiving peritoneal dialysis, fever, upper respiratory infection, cough, pharyngitis, and constipation. The rates are similar between the treatment groups for each event.

Hypertension: Increases in blood pressure have been reported in clinical trials, often during the first 90 days of therapy. On occasion, hypertensive encephalopathy and seizures have been observed in patients with CRF treated with EPOGEN®. When data from all patients in the US phase 3 multicenter trial were analyzed, there was an apparent trend of more reports of hypertensive adverse events in patients on dialysis with a faster rate of rise of hematocrit (greater than 4 hematocrit points in any 2-week period). However, in a double-blind, placebo-controlled trial, hypertensive adverse events were not reported at an increased rate in the group treated with EPOGEN® (150 Units/kg TIW) relative to the placebo group.

Seizures: There have been 47 seizures in 1010 patients on dialysis treated with EPOGEN® in clinical trials, with an exposure of 986 patient-years for a rate of approximately 0.048 events per patient-year. However, there appeared to be a higher rate of seizures during the first 90 days of therapy (occurring in approximately 2.5% of patients) when compared to subsequent 90-day periods. The base-line incidence of seizures in the untreated dialysis population is difficult to determine; it appears to be in the range of 5% to 10% per patient-year.³⁹⁻⁴¹

Thrombotic Events: In clinical trials where the maintenance hematocrit was 35 ± 3% on EPOGEN®, clotting of the vascular access (A-V shunt) has occurred at an annualized rate of about 0.25 events per patient-year, and other thrombotic events (eg, myocardial infarction, cerebral vascular accident, transient ischemic attack, and pulmonary embolism) occurred at a rate of 0.04 events per patient-year. In a separate study of 1111 untreated dialysis patients, clotting of the vascular access occurred at a rate of 0.50 events per patient-year. However, in CRF patients on hemodialysis who also had clinically evident ischemic heart disease or congestive heart failure, the risk of A-V shunt thrombosis was higher (39% vs 29%, p < 0.001), and myocardial infarctions, vascular ischemic events, and venous thrombosis were increased, in patients targeted to a hematocrit of 42 ± 3% compared to those maintained at 30 ± 3% (see WARNINGS).

In patients treated with commercial EPOGEN®, there have been rare reports of serious or unusual thrombo-embolic events including migratory thrombophlebitis, microvascular thrombosis, pulmonary embolus, and thrombosis of the retinal artery, and temporal and renal veins. A causal relationship has not been established.

Allergic Reactions: There have been no reports of serious allergic reactions or anaphylaxis associated with EPOGEN® administration during clinical trials. Skin rashes and urticaria have been observed rarely and when reported have generally been mild and transient in nature.

There have been rare reports of potentially serious allergic reactions including urticaria with associated respiratory symptoms or circumoral edema, or urticaria alone. Most reactions occurred in situations where a causal relationship could not be established. Symptoms recurred with rechallenge in a few instances, suggesting that allergic reactivity may occasionally be associated with EPOGEN® therapy.

There has been no evidence for development of antibodies to erythropoietin in patients tested to date, including those receiving EPOGEN® for over 4 years. Nevertheless, if an anaphylactoid reaction occurs, EPOGEN® should be immediately discontinued and appropriate therapy initiated.

Zidovudine-treated HIV-infected Patients

Adverse events reported in clinical trials with EPOGEN® in zidovudine-treated HIV-infected patients were consistent with the progression of HIV infection. In double-blind, placebo-controlled studies of 3 months duration involving approximately 300 zidovudine-treated HIV-infected patients, adverse events with an incidence of > 10% in either patients treated with EPOGEN® or placebo-treated patients were:

Event	Percent of Patients Reporting Event	
	Patients Treated With EPOGEN® (n = 144)	Placebo-treated Patients (n = 153)
Pyrexia	38%	29%
Fatigue	25%	31%
Headache	19%	14%
Cough	18%	14%
Diarrhea	16%	18%
Rash	16%	8%
Congestion, Respiratory	15%	10%
Nausea	15%	12%
Shortness of Breath	14%	13%
Asthenia	11%	14%
Skin Reaction, Medication Site	10%	7%
Dizziness	9%	10%

There were no statistically significant differences between treatment groups in the incidence of the above events.

In the 297 patients studied, EPOGEN® was not associated with significant increases in opportunistic infections or mortality.²⁵ In 71 patients from this group treated with EPOGEN® at 150 Units/kg TIW, serum p24 antigen levels did not appear to increase.²⁷ Preliminary data showed no enhancement of HIV replication in infected cell lines in vitro.²⁵

Peripheral white blood cell and platelet counts are unchanged following EPOGEN® therapy.

Allergic Reactions: Two zidovudine-treated HIV-infected patients had urticarial reactions within 48 hours of their first exposure to study medication. One patient was treated with EPOGEN® and one was treated with placebo (EPOGEN® vehicle alone). Both patients had positive immediate skin tests against their study medication with a negative saline control. The basis for this apparent pre-existing hypersensitivity to components of the EPOGEN® formula-tion is unknown, but may be related to HIV-induced immunosuppression or prior exposure to blood products.

EPOGEN® (Epoetin alfa)	10
------------------------	----

Seizures: In double-blind and open-label trials of EPOGEN® in zidovudine-treated HIV-infected patients, 10 patients have experienced seizures.²⁵ In general, these seizures appear to be related to underlying pathology such as meningitis or cerebral neoplasms, not EPOGEN® therapy.

Cancer Patients on Chemotherapy

Adverse experiences reported in clinical trials with EPOGEN® in cancer patients were consistent with the underlying disease state. In double-blind, placebo-controlled studies of up to 3 months duration involving 131 cancer patients, adverse events with an incidence > 10% in either patients treated with EPOGEN® or placebo-treated patients were as indicated below.

Event	Percent of Patients Reporting Event	
	Patients Treated With EPOGEN® (n = 63)	Placebo-treated Patients (n = 68)
Pyrexia	29%	19%
Diarrhea	21% ^a	7%
Nausea	17% ^b	32%
Vomiting	17%	15%
Edema	17% ^c	1%
Asthenia	13%	16%
Fatigue	13%	15%
Shortness of Breath	13%	9%
Parasthesia	11%	6%
Upper Respiratory Infection	11%	4%
Dizziness	5%	12%
Trunk Pain	3% ^d	16%

^a p = 0.041, ^b p = 0.069, ^c p = 0.0016, ^d p = 0.017

Although some statistically significant differences between patients being treated with EPOGEN® and placebo-treated patients were noted, the overall safety profile of EPOGEN® appeared to be consistent with the disease process of advanced cancer. During double-blind and subsequent open-label therapy in which patients (n = 72 for total exposure to EPOGEN®) were treated for up to 32 weeks with doses as high as 927 Units/kg, the adverse experience profile of EPOGEN® was consistent with the progression of advanced cancer.

Based on comparable survival data and on the percentage of patients treated with EPOGEN® and placebo-treated patients who discontinued therapy due to death, disease progression, or adverse experiences (22% and 13%, respectively; p = 0.25), the clinical outcome in patients treated with EPOGEN® and placebo-treated patients appeared to be similar. Available data from animal tumor models and measurement of proliferation of solid tumor cells from clinical biopsy specimens in response to EPOGEN® suggest that EPOGEN® does not potentiate tumor growth. Nevertheless, as a growth factor, the possibility that EPOGEN® may potentiate growth of some tumors, particularly myeloid tumors, cannot be excluded. A randomized controlled phase 4 study is currently ongoing to further evaluate this issue.

The mean peripheral white blood cell count was unchanged following EPOGEN® therapy compared to the corresponding value in the placebo-treated group.

Surgery Patients

Adverse events with an incidence of ≥ 10% are shown in the following table:

Event	Percent of Patients Reporting Event				
	Patients Treated With EPOGEN® 300 U/kg (n = 112) ^a	Patients Treated With EPOGEN® 100 U/kg (n = 101) ^a	Placebo-treated Patients (n = 103) ^a	Patients Treated With EPOGEN® 600 U/kg (n = 73) ^b	Patients Treated With EPOGEN® 300 U/kg (n = 72) ^b
Pyrexia	51%	50%	60%	47%	42%
Nausea	48%	43%	45%	45%	58%
Constipation	43%	42%	43%	51%	53%
Skin Reaction, Medication Site	25%	19%	22%	26%	29%
Vomiting	22%	12%	14%	21%	29%
Skin Pain	18%	18%	17%	5%	4%
Pruiritus	16%	16%	14%	14%	22%
Insomnia	13%	16%	13%	21%	18%
Headache	13%	11%	9%	10%	19%
Dizziness	12%	9%	12%	11%	21%
Urinary Tract Infection	12%	3%	11%	11%	8%
Hypertension	10%	11%	10%	5%	10%
Diarrhea	10%	7%	12%	10%	6%
Deep Venous Thrombosis	10%	3%	5%	0% ^c	0% ^c
Dyspepsia	9%	11%	6%	7%	8%
Anxiety	7%	2%	11%	11%	4%
Edema	6%	11%	8%	11%	7%

^a Study including patients undergoing orthopedic surgery treated with EPOGEN® or placebo for 15 days

^b Study including patients undergoing orthopedic surgery treated with EPOGEN® 600 Units/kg weekly x 4 or 300 Units/kg daily x 15

^c Determined by clinical symptoms

Thrombotic/Vascular Events: In three double-blind, placebo-controlled orthopedic surgery studies, the rate of deep venous thrombosis (DVT) was similar among Epoetin alfa and placebo-treated patients in the recommended population of patients with a pretreatment hemoglobin of > 10 to ≤ 13 g/dL.^{18,20,28} However, in 2 of 3 orthopedic surgery studies the overall rate (all pretreatment hemoglobin groups combined) of DVTs detected by postoperative ultrasonography and/or surveillance venography was higher in the group treated with Epoetin alfa than in the placebo-treated group (11% vs 6%). This finding was attributable to the difference in DVT rates observed in the subgroup of patients with pretreatment hemoglobin > 13 g/dL. However, the incidence of DVTs was within the range of that reported in the literature for orthopedic surgery patients.

In the orthopedic surgery study of patients with pretreatment hemoglobin of > 10 to ≤ 13 g/dL, which compared two dosing regimens (600 Units/kg weekly x 4 and

EPOGEN® (Epoetin alfa)	11
------------------------	----

300 Units/kg daily x 15), 4 subjects in the 600 Units/kg weekly EPOGEN® group (5%) and no subjects in the 300 Units/kg daily group had a thrombotic vascular event during the study period.¹⁹

In a study examining the use of Epoetin alfa in 182 patients scheduled for coronary artery bypass graft surgery, 23% of patients treated with Epoetin alfa and 29% treated with placebo experienced thrombotic/vascular events. There were 4 deaths among the Epoetin alfa-treated patients that were associated with a thrombotic/vascular event. A causative role of Epoetin alfa cannot be excluded (see WARNINGS).

OVERDOSAGE

The maximum amount of EPOGEN® that can be safely administered in single or multiple doses has not been determined. Doses of up to 1500 Units/kg TIW for 3 to 4 weeks have been administered to adults without any direct toxic effects of EPOGEN® itself.⁶ Therapy with EPOGEN® can result in polycythemia if the hematocrit is not carefully monitored and the dose appropriately adjusted. If the suggested target range is exceeded, EPOGEN® may be temporarily withheld until the hematocrit returns to the suggested target range; EPOGEN® therapy may then be resumed using a lower dose (see DOSAGE AND ADMINISTRATION). If polycythemia is of concern, phlebotomy may be indicated to decrease the hematocrit.

DOSAGE AND ADMINISTRATION

Chronic Renal Failure Patients

The recommended range for the starting dose of EPOGEN® is 50 to 100 Units/kg TIW for adult patients. The recommended starting dose for pediatric CRF patients on dialysis is 50 Units/kg TIW. The dose of EPOGEN® should be reduced as the hematocrit approaches 36% or increases by more than 4 points in any 2-week period. The dosage of EPOGEN® must be individualized to maintain the hematocrit within the suggested target range. At the physician's discretion, the suggested target hematocrit range may be expanded to achieve maximal patient benefit.

EPOGEN® may be given either as an IV or SC injection. In patients on hemodialysis, EPOGEN® usually has been administered as an IV bolus TIW. While the administration of EPOGEN® is independent of the dialysis procedure, EPOGEN® may be administered into the venous line at the end of the dialysis procedure to obviate the need for additional venous access. In adult patients with CRF not on dialysis, EPOGEN® may be given either as an IV or SC injection.

Patients who have been judged competent by their physicians to self-administer EPOGEN® without medical or other supervision may give themselves either an IV or SC injection. The table below provides general therapeutic guidelines for patients with CRF:

Starting Dose:	
Adults	50 to 100 Units/kg TIW; IV or SC
Pediatric Patients	50 Units/kg TIW; IV or SC
Reduce Dose When:	1. Hct. approaches 36% or, <p>2. Hct. increases > 4 points in any 2-week period</p>

Increase Dose If: Hct. does not increase by 5 to 6 points after 8 weeks of therapy, and hct. is below suggested target range

Maintenance Dose: Individually titrate

Suggested Target Hct. Range:	30% to 36%
-------------------------------------	------------

During therapy, hematological parameters should be monitored regularly (see LABORATORY MONITORING).

Pretherapy Iron Evaluation: Prior to and during EPOGEN® therapy, the patient's iron stores, including transferrin saturation (serum iron divided by iron binding capacity) and serum ferritin, should be evaluated. Transferrin saturation should be at least 20%, and ferritin should be at least 100 ng/mL. Virtually all patients will eventually require supplemental iron to increase or maintain transferrin saturation to levels that will adequately support erythropoiesis stimulated by EPOGEN®.

Dose Adjustment: Following EPOGEN® therapy, a period of time is required for erythroid progenitors to mature and be released into circulation resulting in an eventual increase in hematocrit. Additionally, red blood cell survival time affects hematocrit and may vary due to uremia. As a result, the time required to elicit a clinically significant change in hematocrit (increase or decrease) following any dose adjustment may be 2 to 6 weeks.

Dose adjustment should not be made more frequently than once a month, unless clinically indicated. After any dose adjustment, the hematocrit should be determined twice weekly for at least 2 to 6 weeks (see LABORATORY MONITORING).

- If the hematocrit is increasing and approaching 36%, the dose should be reduced to maintain the suggested target hematocrit range. If the reduced dose does not stop the rise in hematocrit, and it exceeds 36%, doses should be temporarily withheld until the hematocrit begins to decrease, at which point therapy should be reinitiated at a lower dose.
- At any time, if the hematocrit increases by more than 4 points in a 2-week period, the dose should be immediately decreased. After the dose reduction, the hematocrit should be monitored twice weekly for 2 to 6 weeks, and further dose adjustments should be made as outlined in MAINTENANCE DOSE.

- If a hematocrit increase of 5 to 6 points is not achieved after an 8-week period and iron stores are adequate (see LACK OR LOSS OF RESPONSE), the dose of EPOGEN® may be incrementally increased. Further increases may be made at 4 to 6 week intervals until the desired response is attained.

Maintenance Dose: The maintenance dose must be individualized for each patient on dialysis. In the US phase 3 multicenter trial in patients on hemodialysis, the median maintenance dose was 75 Units/kg TIW, with a range from 12.5 to 525 Units/kg TIW. Almost 10% of the patients required a dose of 25 Units/kg, or less, and approximately 10% of the patients required more than 200 Units/kg TIW to maintain their hematocrit in the suggested target range. In pediatric hemodialysis and peritoneal dialysis patients, the median maintenance dose was 167 Units/kg/week (49 to 447 Units/kg per week) and 76 Units/kg per week (24 to 323 Units/kg/week) administered in divided doses (TIW or BIW), respectively to achieve the target range of 30% to 36%.

If the hematocrit remains below, or falls below, the suggested target range, iron stores should be re-evaluated. If the transferrin saturation is less than 20%,

EPOGEN® (Epoetin alfa)	12
------------------------	----

supplemental iron should be administered. If the transferrin saturation is greater than 20%, the dose of EPOGEN® may be increased. Such dose increases should not be made more frequently than once a month, unless clinically indicated, as the response time of the hematocrit to a dose increase can be 2 to 6 weeks. Hematocrit should be measured twice weekly for 2 to 6 weeks following dose increases. In adult patients with CRF not on dialysis, the maintenance dose must also be individualized. EPOGEN® doses of 75 to 150 Units/kg/week have been shown to maintain hematocrits of 36% to 38% for up to 6 months.

Lack or Loss of Response: Over 95% of patients with CRF responded with clinically significant increases in hematocrit, and virtually all patients were transfusion-independent within approximately 2 months of initiation of EPOGEN® therapy.

If a patient fails to respond or maintain a response, other etiologies should be considered and evaluated as clinically indicated (see PRECAUTIONS for discussion of lack or loss of response).

Zidovudine-treated HIV-infected Patients

Prior to beginning EPOGEN®, it is recommended that the endogenous serum erythropoietin level be determined (prior to transfusion). Available evidence suggests that patients receiving zidovudine with endogenous serum erythropoietin levels > 500 mUnits/mL are unlikely to respond to therapy with EPOGEN®.

Starting Dose: For adult patients with serum erythropoietin levels ≤ 500 mUnits/mL who are receiving a dose of zidovudine ≤ 4200 mg/week, the recommended starting dose of EPOGEN® is 100 Units/kg as an IV or SC injection TIW for 8 weeks. For pediatric patients, see PRECAUTIONS: PEDIATRIC USE.

Increase Dose: During the dose adjustment phase of therapy, the hematocrit should be monitored weekly. If the response is not satisfactory in terms of reducing transfusion requirements or increasing hematocrit after 8 weeks of therapy, the dose of EPOGEN® can be increased by 50 to 100 Units/kg TIW. Response should be evaluated every 4 to 8 weeks thereafter and the dose adjusted accordingly by 50 to 100 Units/kg increments TIW. If patients have not responded satisfactorily to an EPOGEN® dose of 300 Units/kg TIW, it is unlikely that they will respond to higher doses of EPOGEN®.

Maintenance Dose: After attainment of the desired response (ie, reduced transfu-sion requirements or increased hematocrit), the dose of EPOGEN® should be titrated to maintain the response based on factors such as variations in zidovudine dose and the presence of intercurrent infectious or inflammatory episodes. If the hematocrit exceeds 40%, the dose should be discontinued until the hematocrit drops to 36%. The dose should be reduced by 25% when treatment is resumed and then titrated to maintain the desired hematocrit.

Cancer Patients on Chemotherapy

Baseline endogenous serum erythropoietin levels varied among patients in these trials with approximately 75% (n = 83/110) having endogenous serum erythro-poietin levels < 132 mUnits/mL, and approximately 4% (n = 4/110) of patients having endogenous serum erythropoietin levels > 500 mUnits/mL. In general, patients with lower baseline serum erythropoietin levels responded more vigorously to EPOGEN® than patients with higher erythropoietin levels. Although no specific serum erythropoietin level can be stipulated above which patients would be unlikely to respond to EPOGEN® therapy, treatment of patients with grossly elevated serum erythropoietin levels (eg, > 200 mUnits/mL) is not recommended. The hematocrit should be monitored on a weekly basis in patients receiving EPOGEN® therapy until hematocrit becomes stable.

Starting Dose: The recommended starting dose of EPOGEN® for adults is 150 Units/kg SC TIW. For pediatric patients, see PRECAUTIONS: PEDIATRIC USE.